GlassScriptPhysician profile
Christopher W Kling
NPI 1467449934
$33,064.91
in general payments reported to CMS, 2019-2025
47 companies · $4,139 in 2025
The $4,139 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,854 · 2020: $3,440 · 2021: $4,007 · 2022: $3,202 · 2023: $4,713 · 2024: $7,709 · 2025: $4,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $3,250 · Education: $631 · Travel and Lodging: $23.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,657.04 |
| Consulting Fee | $3,250.00 |
| Education | $631.13 |
| Travel and Lodging | $23.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,107.04 | 2019-2025 | |
| Ucb, INC. | $4,460.04 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,998.34 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Almirall LLC | $1,658.85 | 2019-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $1,562.40 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,421.29 | 2019-2025 | Absorica Ld, Ilumya |
| Pfizer INC. | $1,409.46 | 2019-2025 | |
| Journey Medical Corporation | $1,360.70 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,205.78 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Novartis Pharmaceuticals Corporation | $1,186.48 | 2019-2025 | |
| Amgen INC. | $1,088.13 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $1,039.56 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $1,009.66 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $908.64 | 2019-2025 | |
| Dermavant Sciences, INC. | $733.78 | 2023-2024 | Vtama |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.